You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
St. Jude Children's Research Hospital researchers evaluated a microbial cell-free DNA sequencing test from infectious disease diagnostics firm Karius.
Effective Feb. 3, 2020, the donor-derived cell-free DNA test will be covered for all kidney transplant recipients, including those with multiple kidney transplants.
Investigators analyzed the expression of protein-coding genes in 18 blood immune cell populations, comparing the expression profiles with those in other cell and tissue types.
The firm did an initial close of its Series A financing round and will pursue additional investments during Q1 2020 when the round is anticipated to close.
Promega said it plans to use the technology to create new research products for investigating endogenous biology.
The financing was led by HealthQuest Capital, with participation from 5AM Ventures and RareCyte founder Ron Seubert, and follows a $30 million round in 2017.
Computational hardware maker Nvidia has purchased Parabricks, which has applied GPU technology to bring whole-genome sequencing processing time under an hour.
As part of the distribution agreement, Biolidics will distribute the IncellDx bioINK kit with Biolidics' ClearCell FX1 system.
The researchers are aiming to provide new insights as to which cancer patients will respond best to immunotherapy based on their genetic backgrounds.
IQvia, the lead investor in this round, will work with BC Platforms to integrate genomic and clinical data in a secure environment to support biomedical research.
Individuals with high genetic susceptibility to heart disease but good sleep habits appeared less likely to develop disease than those with poor sleep patterns.
The Federal Trade Commission has authorized staff to use legal action to block the deal pending an administrative trial, set for August 2020.
The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission.
The company will use the funding to market its GoodCell Diagnostics service, which combines genetic testing and personally controlled biobanking.
With metagenomic sequencing on birch pitch, investigators sequenced a 5,700-year-old individual from Sweden, along with sequences from her meal and her oral microbes.
The company said that it plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications.
Perceptive Advisors led the round, joined by new and existing investors. ArcherDx will use the proceeds to launch a companion diagnostic and expand globally.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
The firm will use the new funds to accelerate development of products, expand partnerships, and support commercialization of its two multiplex panels.
The House bill also includes funding increases for the US Centers for Disease Control and Prevention and the US Food and Drug Administration.
The firm said that with this clearance it now provides a comprehensive menu of VZV and HSV tests from swab and cerebrospinal fluid specimens.
A sequencing study of patients with early-onset dementia often found pathogenic or likely contributory variants in several genes.
A sequencing study suggests circularized DNA may be a more common source of somatic rearrangements in neuroblastoma than previously appreciated.
The Cobas Zika test is for use on Roche's Cobas 6800/8800 systems to screen blood donations and detects Zika virus RNA in samples of human plasma.
NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.
Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.
A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.
In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.